NASDAQ:IRWD - Ironwood Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $12.00 +0.56 (+4.90 %) (As of 04/24/2019 04:18 AM ET)Previous Close$11.44Today's Range$11.43 - $12.1052-Week Range$9.07 - $21.20Volume1.05 million shsAverage Volume1.47 million shsMarket Capitalization$1.86 billionP/E RatioN/ADividend YieldN/ABeta1.91 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. The company pipeline products also include olinciguat, an oral and once-daily vascular sGC stimulator, which is in Phase II trials for the treatment of patients suffering from sickle cell diseases; praliciguat, an oral, once daily systemic sGC stimulator that is in Phase II trials for the treatment of heart failure and for diabetic nephropathy; IW 6463, a central nervous system penetrant oral sGC stimulator in clinical development for serious neurodegenerative diseases; and two organ targeted programs for the treatment of liver and lung. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, Macau, and Japan, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts. Receive IRWD News and Ratings via Email Sign-up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IRWD Previous Symbol CUSIP46333X10 CIK1446847 Webwww.ironwoodpharma.com Phone617-621-7722Debt Debt-to-Equity RatioN/A Current Ratio2.23 Quick Ratio2.23Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$346.64 million Price / Sales5.35 Cash FlowN/A Price / Cash FlowN/A Book Value($1.27) per share Price / Book-9.45Profitability EPS (Most Recent Fiscal Year)($0.95) Net Income$-282,370,000.00 Net Margins-81.46% Return on EquityN/A Return on Assets-29.88%Miscellaneous Employees515 Outstanding Shares154,645,000Market Cap$1.86 billion Next Earnings Date5/2/2019 (Confirmed) OptionableOptionable Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions What is Ironwood Pharmaceuticals' stock symbol? Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD." How were Ironwood Pharmaceuticals' earnings last quarter? Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) issued its earnings results on Wednesday, February, 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.15. The biotechnology company earned $130.70 million during the quarter, compared to analyst estimates of $96.57 million. The firm's revenue was up 38.7% compared to the same quarter last year. During the same period last year, the business earned ($0.14) earnings per share. View Ironwood Pharmaceuticals' Earnings History. When is Ironwood Pharmaceuticals' next earnings date? Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Ironwood Pharmaceuticals. How can I listen to Ironwood Pharmaceuticals' earnings call? Ironwood Pharmaceuticals will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8663934306. What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings? Ironwood Pharmaceuticals issued an update on its FY 2019 earnings guidance on Wednesday, February, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $370-390 million, compared to the consensus revenue estimate of $377.33 million. What price target have analysts set for IRWD? 11 brokerages have issued 1 year price targets for Ironwood Pharmaceuticals' shares. Their forecasts range from $13.00 to $20.00. On average, they anticipate Ironwood Pharmaceuticals' share price to reach $16.50 in the next twelve months. This suggests a possible upside of 37.5% from the stock's current price. View Analyst Price Targets for Ironwood Pharmaceuticals. What is the consensus analysts' recommendation for Ironwood Pharmaceuticals? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ironwood Pharmaceuticals. Has Ironwood Pharmaceuticals been receiving favorable news coverage? News coverage about IRWD stock has been trending somewhat positive recently, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Ironwood Pharmaceuticals earned a daily sentiment score of 1.6 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. Who are some of Ironwood Pharmaceuticals' key competitors? Some companies that are related to Ironwood Pharmaceuticals include Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), Catalent (CTLT), Amarin (AMRN), GALAPAGOS NV/S (GLPG), Nektar Therapeutics (NKTR), Alkermes (ALKS), GW Pharmaceuticals PLC- (GWPH), Array Biopharma (ARRY), Horizon Pharma (HZNP), Ascendis Pharma A/S (ASND), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), TESARO (TSRO) and HUTCHISON CHINA/S (HCM). What other stocks do shareholders of Ironwood Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Micron Technology (MU), YY (YY), Allergan (AGN) and Aegean Marine Petroleum Network (ANW). Who are Ironwood Pharmaceuticals' key executives? Ironwood Pharmaceuticals' management team includes the folowing people: Dr. Peter M. Hecht, Co-Founder, CEO & Director (Age 55)Mr. Thomas A. McCourt, Pres (Age 62)Ms. Gina R. Consylman CPA, CFO, Sr. VP & Treasurer (Age 46)Ms. Halley E. Gilbert, Sr. VP, Chief Legal Officer & Sec. (Age 49)Dr. Christopher I. Wright, Chief Devel. Officer & Sr. VP of Global Devel. Who are Ironwood Pharmaceuticals' major shareholders? Ironwood Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Tibra Equities Europe Ltd (0.04%) and First Manhattan Co. (0.03%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals. Which major investors are buying Ironwood Pharmaceuticals stock? IRWD stock was bought by a variety of institutional investors in the last quarter, including Tibra Equities Europe Ltd and First Manhattan Co.. View Insider Buying and Selling for Ironwood Pharmaceuticals. How do I buy shares of Ironwood Pharmaceuticals? Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Ironwood Pharmaceuticals' stock price today? One share of IRWD stock can currently be purchased for approximately $12.00. How big of a company is Ironwood Pharmaceuticals? Ironwood Pharmaceuticals has a market capitalization of $1.86 billion and generates $346.64 million in revenue each year. The biotechnology company earns $-282,370,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis. Ironwood Pharmaceuticals employs 515 workers across the globe. What is Ironwood Pharmaceuticals' official website? The official website for Ironwood Pharmaceuticals is http://www.ironwoodpharma.com. How can I contact Ironwood Pharmaceuticals? Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected] MarketBeat Community Rating for Ironwood Pharmaceuticals (NASDAQ IRWD)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 412 (Vote Outperform)Underperform Votes: 501 (Vote Underperform)Total Votes: 913MarketBeat's community ratings are surveys of what our community members think about Ironwood Pharmaceuticals and other stocks. Vote "Outperform" if you believe IRWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRWD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/24/2019 by MarketBeat.com StaffFeatured Article: What is net income?